OTC · Biotechnology

Mesoblast Limited (MEOBF) Stock

$1.70 +0.00% OTC: MEOBF Healthcare

Mesoblast Limited, an Australian biopharmaceutical company established in Melbourne in 2004, specializes in the development and global commercialization of allogeneic cellular medicines. With operations spanning the United States, Australia, Singapore, the United Kingdom, and Switzerland, the firm leverages a proprietary regenerative medicine platform based on specialized mesenchymal lineage cells.

Valuation

MetricValue
Price$1.70
Market Cap$2.20B
P/E Ratio-22.15
P/B Ratio3.66
P/S Ratio32.29
EPS (TTM)$-0.09
52-Week High$2.59
52-Week Low$0.97
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-16.10%
ROA-12.06%
ROCE-22.29%
Gross Margin-53.34%
Operating Margin-223.08%
Net Margin-144.33%
Debt/Equity0.24
Current Ratio1.58

Annual Financials (USD)

Metric20212022202320242025
Revenue$7.0M$10.0M$8.0M$6.0M$17.0M
Operating Profit$-109.0M$-81.0M$-69.0M$-84.0M$-62.0M
Net Profit$-99.0M$-91.0M$-82.0M$-88.0M$-102.0M
EPS$-0.16$-0.13$-0.10$-0.09$-0.09
Op Margin-1463.2%-789.1%-923.7%-1425.7%-363.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$745.0M$662.0M$669.0M$669.0M$785.0M
Total Liabilities$163.0M$165.0M$168.0M$189.0M$187.0M
Cash$137.0M$60.0M$71.0M$63.0M$161.0M
Borrowings$105.0M$107.0M$116.0M$119.0M$128.0M

Latest News

Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy? Zacks · Jul 17, 2026 Mesoblast Completes Treatment Target in Phase 3 Back Pain Trial MT Newswires · Jul 14, 2026 Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain GlobeNewswire · Jul 14, 2026 Sector Update: Healthcare Stocks Advance Premarket Friday MT Newswires · Jul 10, 2026 Sector Update: Healthcare MT Newswires · Jul 10, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-107.0M$-66.0M$-63.0M$-48.0M$-50.0M
Investing Cash Flow$-3.0M$-1.0M$0$0$-1.0M
Financing Cash Flow$5.0M$-4.0M$-11.0M$-12.0M$-4.0M
Net Cash Flow$8.0M$-76.0M$11.0M$-8.0M$99.0M
Free Cash Flow$-108.0M$-66.0M$-64.0M$-49.0M$-51.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.98
EV / EBITDA-32.91
FCF Yield-2.49%
Quick Ratio1.41
Interest Coverage-2.70
Return 1Y75.26%
Return 3Y70.00%
Return 5Y21.43%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BRCTFBioArctic AB (publ) $31.78 -9.20% 125.73 $2.82B 2.61%
CSPHFCStone Pharmaceuticals $0.71 +0.00% -19.48 $1.14B 0.00%
GENSFGenus plc $31.07 +0.00% 30.03 $2.06B 0.97%
NURPFNeuren Pharmaceuticals Limited $13.46 +0.00% 68.94 $1.71B 0.00%
ONTTFOxford Nanopore Technologies plc $1.53 +0.00% -7.57 $1.49B 0.00%

About Mesoblast Limited

Mesoblast Limited, an Australian biopharmaceutical company established in Melbourne in 2004, specializes in the development and global commercialization of allogeneic cellular medicines. With operations spanning the United States, Australia, Singapore, the United Kingdom, and Switzerland, the firm leverages a proprietary regenerative medicine platform based on specialized mesenchymal lineage cells. This technology underpins treatments for a wide spectrum of conditions, including cardiovascular, spinal orthopedic, oncological, hematological, immune-mediated, and inflammatory diseases. The company's advanced pipeline includes several products in Phase III clinical trials. Remestemcel-L is being investigated for steroid-refractory acute graft versus host disease (GvHD) and acute respiratory distress syndrome (ARDS) linked to COVID-19 infection. Rexlemestrocel-L is progressing for advanced chronic heart failure, while MPC-06-ID targets chronic low back pain resulting from degenerative disc disease. Additionally, Mesoblast is developing MPC-300-IV for biologic-refractory rheumatoid arthritis and diabetic nephropathy. Strategic partnerships are integral to Mesoblast's operations. The company collaborates with Tasly Pharmaceutical Group to market MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China. A partnership with JCR Pharmaceuticals Co. Ltd. focuses on wound healing for patients with epidermolysis bullosa. Furthermore, Mesoblast works with Grünenthal to develop and commercialize cell therapy for chronic low back pain.

Mesoblast Limited is headquartered in AU.

Mesoblast Limited (MEOBF) stock trades at $1.70 with a market capitalization of $2.20B. The stock is valued at a price-to-earnings (P/E) ratio of -22.15, price-to-book of 3.66, price-to-sales of 32.29. Over the past 52 weeks the stock has ranged between $0.97 and $2.59, and currently trades 34.4% below its 52-week high.

On profitability, Mesoblast Limited generates a return on equity (ROE) of -16.10%, return on capital employed of -22.29%, an operating margin of -223.08%, a net profit margin of -144.33%.

Official website: www.mesoblast.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides